VRDN Viridian Therapeutics, Inc.
Healthcare$17.24-2.54%ClosedMarket Cap: $1.55B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.77
P/S
21.88
EV/EBITDA
-3.92
DCF Value
$-8.17
FCF Yield
-19.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-543.9%
Net Margin
-508.5%
ROE
-60.7%
ROA
-45.7%
ROIC
-52.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $141.0K | 14.2% | $-116.2M | $-104.9M | $— | — |
| Q4 null | $132.0K | -142.4% | $-122.7M | $-120.4M | $— | — |
| FY null | $70.8M | 100.0% | $-363.4M | $-342.6M | $— | — |
| Q3 null | $70.6M | 100.0% | $-40.0M | $-34.6M | $— | — |
| Q2 null | $75.0K | 100.0% | $-106.8M | $-100.7M | $— | — |
| Q1 null | $72.0K | 100.0% | $-93.9M | $-86.9M | $— | — |
| Q4 null | $72.0K | 100.0% | $-87.5M | $-79.7M | $— | — |
| FY null | $302.0K | 100.0% | $-299.0M | $-269.9M | $— | — |
| Q3 null | $86.0K | 100.0% | $-83.5M | $-76.7M | $— | — |
| Q2 null | $72.0K | 100.0% | $-72.2M | $-65.0M | $— | — |
| Q1 null | $72.0K | 100.0% | $-55.9M | $-48.5M | $— | — |
| Q4 2023 | $72.0K | 100.0% | $-71.5M | $-66.9M | $-1.35 | — |